Rivoceranib mesylate

{
  "id": "MLC-T-ONC-016562",
  "term": "Rivoceranib mesylate",
  "field": "Oncology and biomedicine",
  "definition": "The mesylate salt of rivoceranib, an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.",
  "synonyms": [
    "apatinib mesylate"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/rivoceranib-mesylate/"
}